
Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.
Stefan Weiss, MD, FAAD, is the managing director of dermatology at OM1.

Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.

This Rare Disease Day, Stefan Weiss, MD, MBA, FAAD, of OM1, shares his expertise in AI’s capabilities in dermatology.

From the February cover: Joseph Zabinski, PhD, MEM, and Stefan Weiss, MD, MBA, FAAD, share their expertise into AI’s capabilities in dermatology and specifically, rare diseases such as generalized pustular psoriasis.

The emergence of JAK inhibitors has shown tremendous promise as a novel therapeutic approach.

This month's cover feature delves into the new applications and use of AI in dermatology and considers how AI can support clinicians rather than hinder them.

The addition of an HS dataset adds approximately 26,000 new patient records.

Weiss is the managing director of dermatology at OM1, a data analytics company with a health care focus.

Published: February 19th 2024 | Updated: